All In Biotech

NDA 020796 · Orion Pharma

Comtan

Entacapone · Oral · Catechol-O-Methyltransferase Inhibitor

Novel

Last checked: Nov 19, 2026Latest source record: Feb 22, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1999

Oct 19, 1999

Approved uses

1

Original approval plus efficacy supplements

Registered trials

71

14 Phase 3, 5 recruiting

FAERS reports

4,252

3,020 serious, 653 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 30, 2023.

INDICATIONS Entacapone tablets are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose “wearing-off” in patients with Parkinson’s disease (see CLINICAL PHARMACOLOGY, Clinical Studies). Entacapone tablet’s effectiveness has not been systematically evaluated in patients with Parkinson’s disease who do not experience end-of-dose “wearing-off”.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • COMTAN · ENTACAPONE 200MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Entacapone" as an intervention, any sponsor and status, largest first.

All 71 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hallucination509
  • fall493
  • dyskinesia491
  • drug ineffective356
  • death353
  • parkinson^s disease289
  • confusional state279
  • gait disturbance273
  • tremor273
  • on and off phenomenon259
  • somnolence208
  • fatigue207

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200422
200518
200620
200731
200858
200936
201079
201168
201257
201355
201481
2015105
2016141
2017333
2018333
2019375
2020390
2021409
2022391
2023277
2024317
2025378
2026277

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Orion Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.